<DOC>
	<DOCNO>NCT01681576</DOCNO>
	<brief_summary>This study evaluate effect LCZ696 valsartan natriuresis , diuresis , blood pressure salt-sensitive Asian hypertensive patient .</brief_summary>
	<brief_title>Assessment LCZ696 Valsartan Asian Patients With Salt-sensitive Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Key Written inform consent must obtain study assessment perform . Males females nonchildbearing potential legal age ( least 18 year old define local law ) . Asian patient mild moderate essential hypertension , untreated currently take antihypertensive therapy two drug . Key Women childbearing potential . History angioedema , drugrelated otherwise History hypersensitivity LCZ696 , valsartan , drug similar chemical class . Severe hypertension ( grade 3 WHO classification ; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg ) screen end washout period . History evidence secondary form hypertension , Transient ischemic cerebral attack ( TIA ) 12 month prior screen history stroke . History myocardial infarction , coronary bypass surgery percutaneous coronary intervention ( PCI ) 12 month prior screen . Current history hypertensive retinopathy . Previous current diagnosis heart failure ( NYHA Class IIIV ) . Clinically significant valvular heart disease screening . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>hypertension , salt sensitivity , valsartan , LCZ696</keyword>
</DOC>